Q32 Bio Inc.

NasdaqCM:QTTB Stock Report

Market Cap: US$201.4m

Q32 Bio Future Growth

Future criteria checks 2/6

Q32 Bio's earnings are forecast to decline at 25.1% per annum while its annual revenue is expected to grow at 38.3% per year. EPS is expected to decline by 26.3% per annum.

Key information

-25.1%

Earnings growth rate

-26.33%

EPS growth rate

Biotechs earnings growth25.4%
Revenue growth rate38.3%
Future return on equityn/a
Analyst coverage

Low

Last updated22 May 2026

Recent future growth updates

No updates

Recent updates

Seeking Alpha • May 28

Q32 Bio: "Buy" On Bempikibart Advancement And Mid-2026 Data Catalysts

Summary I initiate Q32 Bio (QTTB) at 'Buy' due to advancing bempikibart for Alopecia Areata and strong upcoming catalysts. Company expects mid-2026 data from both Part B [36-week topline] and Part A OLE of its phase 2a SIGNAL-AA trial. Recent $55M private placement and prior financings extend cash runway into 1H 2028 and beyond, supporting clinical milestones. Sale of ADX-097 to Akebia secures $12M upfront and potential $592M milestones, while retaining core platform assets. Read the full article on Seeking Alpha
Seeking Alpha • Aug 29

Q32 Bio: High-Risk, High-Reward With Bempikibart And ADX-097

Summary Q32 Bio's Bempikibart and ADX-097 are in Phase 2 trials, targeting autoimmune and inflammatory diseases, with significant potential to address unmet medical needs. The company's unique approach of localized inhibition minimizes side effects and enhances efficacy, differentiating it in the biotech sector. Despite a short cash runway, Q32 Bio's recent merger, strategic reacquisition, and $42 million private placement bolstered its financial position. I rate Q32 Bio as a speculative "Buy" due to the promising drug candidates, but caution about potential dilution and research setbacks. Read the full article on Seeking Alpha

Earnings and Revenue Growth Forecasts

NasdaqCM:QTTB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20282-75-86-1105
12/31/20271-63-59-1095
12/31/20261-34-33-285
3/31/20265433-27-27N/A
12/31/20255430-34-34N/A
9/30/2025N/A-42-39-39N/A
6/30/2025N/A-52-54-54N/A
3/31/2025N/A-60-66-66N/A
12/31/2024N/A-48-68-68N/A
9/30/2024-15-61-67-67N/A
6/30/2024-13-57-32-32N/A
3/31/2024-10-46-21-21N/A
12/31/2023-7-54-19-19N/A
9/30/202312-3622N/A
12/31/20227-43-13-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: QTTB's earnings are forecast to decline over the next 3 years (-25.1% per year).

Earnings vs Market: QTTB's earnings are forecast to decline over the next 3 years (-25.1% per year).

High Growth Earnings: QTTB's earnings are forecast to decline over the next 3 years.

Revenue vs Market: QTTB's revenue (38.3% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: QTTB's revenue (38.3% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if QTTB's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/24 09:32
End of Day Share Price 2026/06/24 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Q32 Bio Inc. is covered by 6 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Imogen MansfieldCantor Fitzgerald & Co.
Joseph PantginisH.C. Wainwright & Co.
Joseph CatanzaroMizuho Securities USA LLC